TY - JOUR
T1 - Changes in measles serostatus among HIV-infected zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities
AU - Rainwater-Lovett, Kaitlin
AU - Nkamba, Hope C.
AU - Mubiana-Mbewe, Mwangelwa
AU - Bolton-Moore, Carolyn
AU - Moss, William J.
N1 - Funding Information:
Acknowledgments. We thank the study participants and their caregivers. We also thank Patricia Bwalya, Peter Chisenga, Casey Kabaso, Martha Mponda, Priscilla Mukongolwa, Brenda Muluka, Julius Mwanza, and Hendrix Ndhlovu, who collected data and cared for the participating children. Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (R01AI070018). Potential conflicts of interest. All authors: No reported conflicts.
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Background. In 2010, Zambia had a large measles outbreak, providing an opportunity to measure changes in measles serostatus following highly active antiretroviral therapy (HAART), exposure to measles virus, and revaccination among children infected with human immunodeficiency virus (HIV). Methods. A prospective cohort study of 169 HIV-infected Zambian children aged 9-60 months with a history of measles vaccination was conducted to characterize the effects of HAART and revaccination on measles immunoglobulin G (IgG) serostatus by enzyme immunoassay. Results. Prior to the measles outbreak, only 23% of HIV-infected children were measles IgG seropositive at HAART initiation. After adjusting for 6-month changes in baseline age and 5% changes in nadir CD4+ T-cell percentage, HAART was not associated with measles IgG seroconversion. However, 18 of 19 children seroconverted after revaccination. Eight children seroconverted during the outbreak without revaccination and were likely exposed to wild-type measles virus, but none were reported to have had clinical measles. Conclusions. Immune reconstitution after HAART initiation did not restore protective levels of measles IgG antibodies, but almost all children developed protective antibody levels after revaccination. Some previously vaccinated HIV-infected children had serological evidence of exposure to wild-type measles virus without a reported history of measles.
AB - Background. In 2010, Zambia had a large measles outbreak, providing an opportunity to measure changes in measles serostatus following highly active antiretroviral therapy (HAART), exposure to measles virus, and revaccination among children infected with human immunodeficiency virus (HIV). Methods. A prospective cohort study of 169 HIV-infected Zambian children aged 9-60 months with a history of measles vaccination was conducted to characterize the effects of HAART and revaccination on measles immunoglobulin G (IgG) serostatus by enzyme immunoassay. Results. Prior to the measles outbreak, only 23% of HIV-infected children were measles IgG seropositive at HAART initiation. After adjusting for 6-month changes in baseline age and 5% changes in nadir CD4+ T-cell percentage, HAART was not associated with measles IgG seroconversion. However, 18 of 19 children seroconverted after revaccination. Eight children seroconverted during the outbreak without revaccination and were likely exposed to wild-type measles virus, but none were reported to have had clinical measles. Conclusions. Immune reconstitution after HAART initiation did not restore protective levels of measles IgG antibodies, but almost all children developed protective antibody levels after revaccination. Some previously vaccinated HIV-infected children had serological evidence of exposure to wild-type measles virus without a reported history of measles.
KW - Antibody
KW - Antiretroviral therapy
KW - HIV
KW - Immune reconstitution
KW - Measles
KW - Outbreak
UR - http://www.scopus.com/inward/record.url?scp=84888601985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888601985&partnerID=8YFLogxK
U2 - 10.1093/infdis/jit404
DO - 10.1093/infdis/jit404
M3 - Article
C2 - 23911708
AN - SCOPUS:84888601985
SN - 0022-1899
VL - 208
SP - 1747
EP - 1755
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 11
ER -